Marco D.
- Country
- France
- Department
- Complex Operative Unit of Gastroenterology - largo Turati, 62 Turin
Research Overview
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
Data & Insights
Has run more than one trial at 364 of 568 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in treating inflammatory bowel diseases, with particular emphasis on ulcerative colitis in its moderate to severe forms.
- Novel therapeutic approaches for UC management
- Biological therapy assessment
- Clinical response evaluation in UC patients
Their work involves investigating innovative treatment options for patients with refractory disease conditions.
Therapeutic Innovation
Focus on evaluating emerging biological agents and biosimilar treatments for inflammatory bowel conditions.
- Comparative efficacy studies
- Novel oral therapeutics assessment
- Long-term treatment outcomes
The investigator examines both monotherapy and combination treatment approaches in inflammatory bowel disease management.
Clinical Symptom Management
Specialized research in bowel urgency management and disease severity assessment in ulcerative colitis patients.
- Symptom severity evaluation
- Quality of life improvement
- Treatment response monitoring
Their work encompasses comprehensive assessment of therapeutic interventions on specific disease manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.